Results 141 to 150 of about 638,455 (170)
Some of the next articles are maybe not open access.
Advances in toxic epidermal necrolysis
Seminars in Cutaneous Medicine and Surgery, 1996On the basis of the clinicopathologic and causative characteristics, one can separate an erythema multiformis spectrum from a toxic epidermal necrolysis (TEN)-Stevens Johnson syndrome which is a drug induced disease. Despite a well-known clinical aspect, several cutaneous diseases may be mistaken for TEN.
J E, Revuz, J C, Roujeau
openaire +2 more sources
The management of toxic epidermal necrolysis
Australasian Journal of Dermatology, 2012ABSTRACTThe mortality rate of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is high; approximately 5% for SJS and 25% for TEN. It is therefore vital for the treating physician to recognise SJS and TEN promptly through the identification of these diseases' characteristic clinical features so that the offending drug is promptly ...
openaire +2 more sources
Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review
OncoTargets and Therapy, 2022Tianyi Qian
exaly
Toxic epidermal necrolysis associated with pembrolizumab
Journal of Oncology Pharmacy Practice, 2020Alexandre Mathieu +2 more
exaly
Modified Score of Toxic Epidermal Necrolysis to predict toxic epidermal necrolysis mortality
Journal of the American Academy of Dermatology, 2023Zahra, Haghani Dogahe +3 more
openaire +2 more sources
Etanercept therapy for toxic epidermal necrolysis
Journal of the American Academy of Dermatology, 2014Biagio Didona, Damiano Abeni
exaly